137 related articles for article (PubMed ID: 33439463)
21. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
[TBL] [Abstract][Full Text] [Related]
23. Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea.
Lim S; Li X; Syrkina O; Fournier M
Infect Dis Ther; 2022 Oct; 11(5):2035-2043. PubMed ID: 36070176
[TBL] [Abstract][Full Text] [Related]
24. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
[TBL] [Abstract][Full Text] [Related]
26. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
28. Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis.
Vir Singh P; Tiberi P; Di Domenico GF; Romolini V; Mzolo T; Costantini M; Akhund T; Basile V; Lattanzi M; Pellegrini M
Drug Saf; 2023 Jan; 46(1):99-108. PubMed ID: 36369456
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): a multicenter, open-label, non-randomized, phase III clinical trial.
Yadav S; Manglani MV; Narayan DA; Sharma S; Ravish HS; Arora R; Castells VB; Arya S; Oster P
Indian Pediatr; 2014 Jun; 51(6):451-6. PubMed ID: 24986280
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
34. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
Cooper B; DeTora L; Stoddard J
Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
[TBL] [Abstract][Full Text] [Related]
35. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
[TBL] [Abstract][Full Text] [Related]
38. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
[TBL] [Abstract][Full Text] [Related]
40. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.
Klein NP; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2016 Jun; 35(6):662-72. PubMed ID: 26928521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
